Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

Asuene Raises US$20 million in Series B Round, Aiming to Becom...

TOKYO, Oct. 27, 2022 /Kyodo JBN-AsiaNet/ -- Asuene Inc., the leading climate tech company in Japan, has raised US$20 million in total Series B round. This brings the cumulative total of inve...

Artprice by ArtMarket.com: How to Objectively Define Contempor...

PARIS, January 14, 2020, /PRNewswire-AsiaNet/-- For the sake of coherence, clarity and transparency, Artprice's editorial team has always divided Art History into five main periods with artw...

Dominating Specs and Performance Led to GIGABYTE's Successful ...

TAIPEI, Feb. 18, 2021 /PRNewswire-AsiaNet/ --- With the launch of NVIDIA's new mobile RTX 30 graphics card, GIGABYTE also rolled out its latest-gen pro-gaming AORUS series and creator-aimed...

TECHTRONIC INDUSTRIES DELIVERS EXCEPTIONAL 2021 RESULTS WITH O...

HONG KONG, March 2, 2022 /PRNewswire-AsiaNet/ -- Hong Kong-based global power equipment and floorcare & cleaning company Techtronic Industries Co. Ltd. ("TTI" or the "Group") (stock code...

Organised by World Green Organisation and Proudly Presented by MTR Corporation - Green WALK Hong Kong 2024

Green WALK Hong Kong and Walking Habit Survey Results Press ConferenceSurvey Finds Changes in Travel Habits Among Hong Kong Citizens Let's Adopt a Low-carbon Lifestyle by Walking Every Day ...

Shopee Singapore and Children’s Cancer Foundation Announce Partnership to Support The Hope Train x ARTrepreneur 2024 Initiative

SINGAPORE - Media OutReach Newswire - 4 December 2024 - Shopee, the leading e-commerce platform in Southeast Asia and Taiwan, and the Children’s Cancer Foundation (CCF) are excited to...

And the winner is... Welcome to the International Truck of the...

MILAN, Nov. 19, 2020 /PRNewswire-AsiaNet/ -- Each year, a jury of 24 European commercial vehicle journalists selects a recipient for the 'International Truck of the Year' award. This is no o...

China-EU Regional Economy Cooperation Platform Officially Laun...

CHENGDU, China, June 12, 2019 /PRNewswire-AsiaNet/ -- On June 11, EU-China Smart City and Technology Innovation Forum was held at Business & Innovation Centre for China-Europe Cooperatio...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat